Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 282

1.

Clinical and Dopamine Transporter Imaging Characteristics of Leucine- Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross-Sectional Study.

Simuni T, Brumm MC, Uribe L, Caspell-Garcia C, Coffey CS, Siderowf A, Alcalay R, Trojanowski JQ, Shaw LM, Seibyl J, Singleton A, Toga AW, Galasko D, Foroud T, Nudelman K, Tosun-Turgut D, Poston K, Weintraub D, Mollenhauer B, Tanner CM, Kieburtz K, Chahine LM, Reimer A, Hutten S, Bressman S, Marek K; Parkinson's Progression Markers Initiative Investigators.

Mov Disord. 2020 Feb 19. doi: 10.1002/mds.27989. [Epub ahead of print]

PMID:
32073681
2.

β-adrenoreceptors and the risk of Parkinson's disease.

Hopfner F, Höglinger GU, Kuhlenbäumer G, Pottegård A, Wod M, Christensen K, Tanner CM, Deuschl G.

Lancet Neurol. 2020 Mar;19(3):247-254. doi: 10.1016/S1474-4422(19)30400-4. Epub 2020 Jan 27. Review. Erratum in: Lancet Neurol. 2020 Mar;19(3):e3.

PMID:
31999942
3.

Comparison of an Online-Only Parkinson's Disease Research Cohort to Cohorts Assessed In Person.

Chahine LM, Chin I, Caspell-Garcia C, Standaert DG, Brown E, Smolensky L, Arnedo V, Daeschler D, Riley L, Korell M, Dobkin R, Amondikar N, Gradinscak S, Shoulson I, Dean M, Kwok K, Cannon P, Marek K, Kopil C, Tanner CM, Marrason C; behalf of the Fox Insight Study.

J Parkinsons Dis. 2020 Jan 13. doi: 10.3233/JPD-191808. [Epub ahead of print]

PMID:
31958097
4.

EASE LID 2: A 2-Year Open-Label Trial of Gocovri (Amantadine) Extended Release for Dyskinesia in Parkinson's Disease.

Tanner CM, Pahwa R, Hauser RA, Oertel WH, Isaacson SH, Jankovic J, Johnson R, Chernick D, Hubble J.

J Parkinsons Dis. 2020 Jan 6. doi: 10.3233/JPD-191841. [Epub ahead of print]

PMID:
31929122
5.

Cervical dystonia incidence and diagnostic delay in a multiethnic population.

LaHue SC, Albers K, Goldman S, Lo RY, Gu Z, Leimpeter A, Fross R, Comyns K, Marras C, de Kleijn A, Smit R, Katz M, Ozelius LJ, Bressman S, Saunders-Pullman R, Comella C, Klingman J, Nelson LM, Van Den Eeden SK, Tanner CM.

Mov Disord. 2019 Nov 27. doi: 10.1002/mds.27927. [Epub ahead of print]

PMID:
31774238
6.

Parkinson Disease Epidemiology, Pathology, Genetics, and Pathophysiology.

Simon DK, Tanner CM, Brundin P.

Clin Geriatr Med. 2020 Feb;36(1):1-12. doi: 10.1016/j.cger.2019.08.002. Epub 2019 Aug 24. Review.

PMID:
31733690
7.

A Phase 3, 1-Year, Open-Label Trial of Valbenazine in Adults With Tardive Dyskinesia.

Marder SR, Singer C, Lindenmayer JP, Tanner CM, Comella CL, Verghese C, Jimenez R, Liang GS, Burke J, OʼBrien CF.

J Clin Psychopharmacol. 2019 Nov/Dec;39(6):620-627. doi: 10.1097/JCP.0000000000001111.

PMID:
31688452
8.

Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study.

Simuni T, Uribe L, Cho HR, Caspell-Garcia C, Coffey CS, Siderowf A, Trojanowski JQ, Shaw LM, Seibyl J, Singleton A, Toga AW, Galasko D, Foroud T, Tosun D, Poston K, Weintraub D, Mollenhauer B, Tanner CM, Kieburtz K, Chahine LM, Reimer A, Hutten SJ, Bressman S, Marek K; PPMI Investigators.

Lancet Neurol. 2020 Jan;19(1):71-80. doi: 10.1016/S1474-4422(19)30319-9. Epub 2019 Oct 31.

PMID:
31678032
9.

Excessive daytime sleepiness and topographic expansion of Lewy pathology.

Abbott RD, Ross GW, Duda JE, Shin C, Uyehara-Lock JH, Masaki KH, Launer LJ, White LR, Tanner CM, Petrovitch H.

Neurology. 2019 Oct 8;93(15):e1425-e1432. doi: 10.1212/WNL.0000000000008241. Epub 2019 Aug 30.

PMID:
31471503
10.

Longitudinal analyses of cerebrospinal fluid α-Synuclein in prodromal and early Parkinson's disease.

Mollenhauer B, Caspell-Garcia CJ, Coffey CS, Taylor P, Singleton A, Shaw LM, Trojanowski JQ, Frasier M, Simuni T, Iranzo A, Oertel W, Siderowf A, Weintraub D, Seibyl J, Toga AW, Tanner CM, Kieburtz K, Chahine LM, Marek K, Galasko D; PPMI study.

Mov Disord. 2019 Sep;34(9):1354-1364. doi: 10.1002/mds.27806. Epub 2019 Jul 30.

PMID:
31361367
11.

The NAS-NRC Twin Registry and Duke Twins Study of Memory in Aging: An Update.

Gatz M, Plassman BL, Tanner CM, Goldman SM, Swan GE, Chanti-Ketterl M, Walters EE, Butler DA.

Twin Res Hum Genet. 2019 Jul 29:1-4. doi: 10.1017/thg.2019.45. [Epub ahead of print]

PMID:
31354124
12.

Rotenone and Parkinson's Disease: Reduced Sensitivity in Females.

Goldman SM, Tanner CM.

Toxicol Sci. 2019 Jun 1;170(2):562-563. doi: 10.1093/toxsci/kfz126. No abstract available.

PMID:
31161209
13.

A specific amino acid motif of HLA-DRB1 mediates risk and interacts with smoking history in Parkinson's disease.

Hollenbach JA, Norman PJ, Creary LE, Damotte V, Montero-Martin G, Caillier S, Anderson KM, Misra MK, Nemat-Gorgani N, Osoegawa K, Santaniello A, Renschen A, Marin WM, Dandekar R, Parham P, Tanner CM, Hauser SL, Fernandez-Viña M, Oksenberg JR.

Proc Natl Acad Sci U S A. 2019 Apr 9;116(15):7419-7424. doi: 10.1073/pnas.1821778116. Epub 2019 Mar 25.

14.

Concordance for Parkinson's disease in twins: A 20-year update.

Goldman SM, Marek K, Ottman R, Meng C, Comyns K, Chan P, Ma J, Marras C, Langston JW, Ross GW, Tanner CM.

Ann Neurol. 2019 Apr;85(4):600-605. doi: 10.1002/ana.25441. Epub 2019 Mar 11.

PMID:
30786044
15.

Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases.

Espay AJ, Vizcarra JA, Marsili L, Lang AE, Simon DK, Merola A, Josephs KA, Fasano A, Morgante F, Savica R, Greenamyre JT, Cambi F, Yamasaki TR, Tanner CM, Gan-Or Z, Litvan I, Mata IF, Zabetian CP, Brundin P, Fernandez HH, Standaert DG, Kauffman MA, Schwarzschild MA, Sardi SP, Sherer T, Perry G, Leverenz JB.

Neurology. 2019 Feb 12;92(7):329-337. doi: 10.1212/WNL.0000000000006926. Review.

16.

Feasibility and safety of lumbar puncture in the Parkinson's disease research participants: Parkinson's Progression Marker Initiative (PPMI).

Prakash N, Caspell-Garcia C, Coffey C, Siderowf A, Tanner CM, Kieburtz K, Mollenhauer B, Galasko D, Merchant K, Foroud T, Chahine LM, Weintraub D, Casaceli C, Dorsey R, Wilson R, Herzog M, Daegele N, Arnedo V, Frasier M, Sherer T, Marek K, Frank S, Jennings D, Simuni T; Parkinson's Progression Markers InitiativeSteering Committee; Study Cores; Site Investigators; Coordinators; Industry and Scientific Advisory Board.

Parkinsonism Relat Disord. 2019 May;62:201-209. doi: 10.1016/j.parkreldis.2018.12.025. Epub 2019 Jan 31.

PMID:
30738748
17.

Association of brain heptachlor epoxide and other organochlorine compounds with lewy pathology.

Ross GW, Abbott RD, Petrovitch H, Duda JE, Tanner CM, Zarow C, Uyehara-Lock JH, Masaki KH, Launer LJ, Studabaker WB, White LR.

Mov Disord. 2019 Feb;34(2):228-235. doi: 10.1002/mds.27594. Epub 2018 Dec 30.

18.

The Parkinson's progression markers initiative (PPMI) - establishing a PD biomarker cohort.

Marek K, Chowdhury S, Siderowf A, Lasch S, Coffey CS, Caspell-Garcia C, Simuni T, Jennings D, Tanner CM, Trojanowski JQ, Shaw LM, Seibyl J, Schuff N, Singleton A, Kieburtz K, Toga AW, Mollenhauer B, Galasko D, Chahine LM, Weintraub D, Foroud T, Tosun-Turgut D, Poston K, Arnedo V, Frasier M, Sherer T; Parkinson's Progression Markers Initiative.

Ann Clin Transl Neurol. 2018 Oct 31;5(12):1460-1477. doi: 10.1002/acn3.644. eCollection 2018 Dec.

19.

Occupational exposures and parkinsonism among Shanghai women textile workers.

Checkoway H, Ilango S, Li W, Ray RM, Tanner CM, Hu SC, Wang X, Nielsen S, Gao DL, Thomas DB.

Am J Ind Med. 2018 Nov;61(11):886-892. doi: 10.1002/ajim.22906. Epub 2018 Sep 9.

PMID:
30198067
20.

Mendel and urate: Acid test or random noise?

Brown EG, Goldman SM, Tanner CM.

Parkinsonism Relat Disord. 2018 Aug;53:1-3. doi: 10.1016/j.parkreldis.2018.08.005. Epub 2018 Aug 7. No abstract available.

PMID:
30100365
21.

Prevalence of Parkinson's disease across North America.

Marras C, Beck JC, Bower JH, Roberts E, Ritz B, Ross GW, Abbott RD, Savica R, Van Den Eeden SK, Willis AW, Tanner CM; Parkinson’s Foundation P4 Group.

NPJ Parkinsons Dis. 2018 Jul 10;4:21. doi: 10.1038/s41531-018-0058-0. eCollection 2018.

22.

Parkinson's Patients with Dyskinesia Switched from Immediate Release Amantadine to Open-label ADS-5102.

Isaacson SH, Fahn S, Pahwa R, Tanner CM, Espay AJ, Trenkwalder C, Adler CH, Patni R, Johnson R.

Mov Disord Clin Pract. 2018 Mar-Apr;5(2):183-190. doi: 10.1002/mdc3.12595. Epub 2018 Feb 23.

23.

Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative Cohort.

Simuni T, Siderowf A, Lasch S, Coffey CS, Caspell-Garcia C, Jennings D, Tanner CM, Trojanowski JQ, Shaw LM, Seibyl J, Schuff N, Singleton A, Kieburtz K, Toga AW, Mollenhauer B, Galasko D, Chahine LM, Weintraub D, Foroud T, Tosun D, Poston K, Arnedo V, Frasier M, Sherer T, Chowdhury S, Marek K; Parkinson's Progression Marker Initiative*.

Mov Disord. 2018 May;33(5):771-782. doi: 10.1002/mds.27361. Epub 2018 Mar 23.

24.

Telemedicine Use for Movement Disorders: A Global Survey.

Hassan A, Dorsey ER, Goetz CG, Bloem BR, Guttman M, Tanner CM, Mari Z, Pantelyat A, Galifianakis NB, Bajwa JA, Gatto EM, Cubo E.

Telemed J E Health. 2018 Dec;24(12):979-992. doi: 10.1089/tmj.2017.0295. Epub 2018 Mar 22.

PMID:
29565764
25.

Excessive burden of lysosomal storage disorder gene variants in Parkinson's disease.

Robak LA, Jansen IE, van Rooij J, Uitterlinden AG, Kraaij R, Jankovic J; International Parkinson’s Disease Genomics Consortium (IPDGC), Heutink P, Shulman JM.

Brain. 2017 Dec 1;140(12):3191-3203. doi: 10.1093/brain/awx285.

26.

Baseline prevalence and longitudinal evolution of non-motor symptoms in early Parkinson's disease: the PPMI cohort.

Simuni T, Caspell-Garcia C, Coffey CS, Weintraub D, Mollenhauer B, Lasch S, Tanner CM, Jennings D, Kieburtz K, Chahine LM, Marek K.

J Neurol Neurosurg Psychiatry. 2018 Jan;89(1):78-88. doi: 10.1136/jnnp-2017-316213. Epub 2017 Oct 6.

27.

Lessons Learned From Past Gene-Environment Interaction Successes.

Ritz BR, Chatterjee N, Garcia-Closas M, Gauderman WJ, Pierce BL, Kraft P, Tanner CM, Mechanic LE, McAllister K.

Am J Epidemiol. 2017 Oct 1;186(7):778-786. doi: 10.1093/aje/kwx230. Review.

28.

Impaired Cognition and the Risk of Parkinson Disease: Trouble in Mind.

Brown EG, Tanner CM.

JAMA Neurol. 2017 Dec 1;74(12):1398-1400. doi: 10.1001/jamaneurol.2017.1474. No abstract available.

PMID:
28973080
29.

Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy.

Obeso JA, Stamelou M, Goetz CG, Poewe W, Lang AE, Weintraub D, Burn D, Halliday GM, Bezard E, Przedborski S, Lehericy S, Brooks DJ, Rothwell JC, Hallett M, DeLong MR, Marras C, Tanner CM, Ross GW, Langston JW, Klein C, Bonifati V, Jankovic J, Lozano AM, Deuschl G, Bergman H, Tolosa E, Rodriguez-Violante M, Fahn S, Postuma RB, Berg D, Marek K, Standaert DG, Surmeier DJ, Olanow CW, Kordower JH, Calabresi P, Schapira AHV, Stoessl AJ.

Mov Disord. 2017 Sep;32(9):1264-1310. doi: 10.1002/mds.27115. Review.

30.

Virtual visits for Parkinson disease: A multicenter noncontrolled cohort.

Korn RE, Wagle Shukla A, Katz M, Keenan HT, Goldenthal S, Auinger P, Zhu W, Dodge M, Rizer K, Achey MA, Byrd E, Barbano R, Richard I, Andrzejewski KL, Schwarz HB, Dorsey ER, Biglan KM, Kang G, Kanchana S, Rodriguez R, Tanner CM, Galifianakis NB.

Neurol Clin Pract. 2017 Aug;7(4):283-295. doi: 10.1212/CPJ.0000000000000371.

31.

Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3).

Oertel W, Eggert K, Pahwa R, Tanner CM, Hauser RA, Trenkwalder C, Ehret R, Azulay JP, Isaacson S, Felt L, Stempien MJ.

Mov Disord. 2017 Dec;32(12):1701-1709. doi: 10.1002/mds.27131. Epub 2017 Aug 21.

32.

National randomized controlled trial of virtual house calls for Parkinson disease.

Beck CA, Beran DB, Biglan KM, Boyd CM, Dorsey ER, Schmidt PN, Simone R, Willis AW, Galifianakis NB, Katz M, Tanner CM, Dodenhoff K, Aldred J, Carter J, Fraser A, Jimenez-Shahed J, Hunter C, Spindler M, Reichwein S, Mari Z, Dunlop B, Morgan JC, McLane D, Hickey P, Gauger L, Richard IH, Mejia NI, Bwala G, Nance M, Shih LC, Singer C, Vargas-Parra S, Zadikoff C, Okon N, Feigin A, Ayan J, Vaughan C, Pahwa R, Dhall R, Hassan A, DeMello S, Riggare SS, Wicks P, Achey MA, Elson MJ, Goldenthal S, Keenan HT, Korn R, Schwarz H, Sharma S, Stevenson EA, Zhu W; Connect.Parkinson Investigators.

Neurology. 2017 Sep 12;89(11):1152-1161. doi: 10.1212/WNL.0000000000004357. Epub 2017 Aug 16.

33.

ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson's Disease (EASE LID 2 Study): Interim Results of an Open-Label Safety Study.

Hauser RA, Pahwa R, Tanner CM, Oertel W, Isaacson SH, Johnson R, Felt L, Stempien MJ.

J Parkinsons Dis. 2017;7(3):511-522. doi: 10.3233/JPD-171134.

34.

Prediction of cognition in Parkinson's disease with a clinical-genetic score: a longitudinal analysis of nine cohorts.

Liu G, Locascio JJ, Corvol JC, Boot B, Liao Z, Page K, Franco D, Burke K, Jansen IE, Trisini-Lipsanopoulos A, Winder-Rhodes S, Tanner CM, Lang AE, Eberly S, Elbaz A, Brice A, Mangone G, Ravina B, Shoulson I, Cormier-Dequaire F, Heutink P, van Hilten JJ, Barker RA, Williams-Gray CH, Marinus J, Scherzer CR; HBS; CamPaIGN; PICNICS; PROPARK; PSG; DIGPD; PDBP.

Lancet Neurol. 2017 Aug;16(8):620-629. doi: 10.1016/S1474-4422(17)30122-9. Epub 2017 Jun 16. Erratum in: Lancet Neurol. 2017 Sep;16(9):683.

35.

Marinesco bodies and substantia nigra neuron density in Parkinson's disease.

Abbott RD, Nelson JS, Ross GW, Uyehara-Lock JH, Tanner CM, Masaki KH, Launer LJ, White LR, Petrovitch H.

Neuropathol Appl Neurobiol. 2017 Dec;43(7):621-630. doi: 10.1111/nan.12419. Epub 2017 Jul 9.

36.

ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study): A Randomized Clinical Trial.

Pahwa R, Tanner CM, Hauser RA, Isaacson SH, Nausieda PA, Truong DD, Agarwal P, Hull KL, Lyons KE, Johnson R, Stempien MJ.

JAMA Neurol. 2017 Aug 1;74(8):941-949. doi: 10.1001/jamaneurol.2017.0943.

37.

Parkinson disease.

Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, Schrag AE, Lang AE.

Nat Rev Dis Primers. 2017 Mar 23;3:17013. doi: 10.1038/nrdp.2017.13. Review.

PMID:
28332488
38.

Caffeine, creatine, GRIN2A and Parkinson's disease progression.

Simon DK, Wu C, Tilley BC, Lohmann K, Klein C, Payami H, Wills AM, Aminoff MJ, Bainbridge J, Dewey R, Hauser RA, Schaake S, Schneider JS, Sharma S, Singer C, Tanner CM, Truong D, Wei P, Wong PS, Yang T.

J Neurol Sci. 2017 Apr 15;375:355-359. doi: 10.1016/j.jns.2017.02.032. Epub 2017 Feb 17.

39.

Biomarker-driven phenotyping in Parkinson's disease: A translational missing link in disease-modifying clinical trials.

Espay AJ, Schwarzschild MA, Tanner CM, Fernandez HH, Simon DK, Leverenz JB, Merola A, Chen-Plotkin A, Brundin P, Kauffman MA, Erro R, Kieburtz K, Woo D, Macklin EA, Standaert DG, Lang AE.

Mov Disord. 2017 Mar;32(3):319-324. doi: 10.1002/mds.26913. Epub 2017 Feb 24. Review.

40.

No genetic association between attention-deficit/hyperactivity disorder (ADHD) and Parkinson's disease in nine ADHD candidate SNPs.

Geissler JM; International Parkinson Disease Genomics Consortium members, Romanos M, Gerlach M, Berg D, Schulte C.

Atten Defic Hyperact Disord. 2017 Jun;9(2):121-127. doi: 10.1007/s12402-017-0219-8. Epub 2017 Feb 7.

41.

Discovery and functional prioritization of Parkinson's disease candidate genes from large-scale whole exome sequencing.

Jansen IE, Ye H, Heetveld S, Lechler MC, Michels H, Seinstra RI, Lubbe SJ, Drouet V, Lesage S, Majounie E, Gibbs JR, Nalls MA, Ryten M, Botia JA, Vandrovcova J, Simon-Sanchez J, Castillo-Lizardo M, Rizzu P, Blauwendraat C, Chouhan AK, Li Y, Yogi P, Amin N, van Duijn CM; International Parkinson’s Disease Genetics Consortium (IPGDC), Morris HR, Brice A, Singleton AB, David DC, Nollen EA, Jain S, Shulman JM, Heutink P.

Genome Biol. 2017 Jan 30;18(1):22. doi: 10.1186/s13059-017-1147-9.

42.

Heart rate variability in leucine-rich repeat kinase 2-associated Parkinson's disease.

Visanji NP, Bhudhikanok GS, Mestre TA, Ghate T, Udupa K, AlDakheel A, Connolly BS, Gasca-Salas C, Kern DS, Jain J, Slow EJ, Faust-Socher A, Kim S, Azhu Valappil R, Kausar F, Rogaeva E, William Langston J, Tanner CM, Schüle B, Lang AE, Goldman SM, Marras C.

Mov Disord. 2017 Apr;32(4):610-614. doi: 10.1002/mds.26896. Epub 2017 Jan 10.

PMID:
28071824
43.

Knowledge gaps and research recommendations for essential tremor.

Hopfner F, Haubenberger D, Galpern WR, Gwinn K, Van't Veer A, White S, Bhatia K, Adler CH, Eidelberg D, Ondo W, Stebbins GT, Tanner CM, Helmich RC, Lenz FA, Sillitoe RV, Vaillancourt D, Vitek JL, Louis ED, Shill HA, Frosch MP, Foroud T, Kuhlenbäumer G, Singleton A, Testa CM, Hallett M, Elble R, Deuschl G.

Parkinsonism Relat Disord. 2016 Dec;33:27-35. doi: 10.1016/j.parkreldis.2016.10.002. Epub 2016 Oct 4. Review.

44.

Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's.

Liu G, Boot B, Locascio JJ, Jansen IE, Winder-Rhodes S, Eberly S, Elbaz A, Brice A, Ravina B, van Hilten JJ, Cormier-Dequaire F, Corvol JC, Barker RA, Heutink P, Marinus J, Williams-Gray CH, Scherzer CR; International Genetics of Parkinson Disease Progression (IGPP) Consortium.

Ann Neurol. 2016 Nov;80(5):674-685. doi: 10.1002/ana.24781.

45.

Role of Neuroinflammation in Parkinson Disease: The Enigma Continues.

Mehta SH, Tanner CM.

Mayo Clin Proc. 2016 Oct;91(10):1328-1330. doi: 10.1016/j.mayocp.2016.08.010. No abstract available.

PMID:
27712631
46.

The best medicine? The influence of physical activity and inactivity on Parkinson's disease.

LaHue SC, Comella CL, Tanner CM.

Mov Disord. 2016 Oct;31(10):1444-1454. doi: 10.1002/mds.26728. Review.

PMID:
27477046
47.

Predictors of time to initiation of symptomatic therapy in early Parkinson's disease.

Simuni T, Long JD, Caspell-Garcia C, Coffey CS, Lasch S, Tanner CM, Jennings D, Kieburtz KD, Marek K; PPMI Investigators.

Ann Clin Transl Neurol. 2016 May 17;3(7):482-94. doi: 10.1002/acn3.317. eCollection 2016 Jul.

48.

Problematic Mobile Gaming in Parkinson's Disease: An Impulse Control Disorder for the Smartphone.

Galifianakis NB, Byrd EA, Ostrem JL, Tanner CM, Racine CA.

Mov Disord Clin Pract. 2016 Jun 17;4(2):277-278. doi: 10.1002/mdc3.12378. eCollection 2017 Mar-Apr. No abstract available.

49.

CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative study.

Kang JH, Mollenhauer B, Coffey CS, Toledo JB, Weintraub D, Galasko DR, Irwin DJ, Van Deerlin V, Chen-Plotkin AS, Caspell-Garcia C, Waligórska T, Taylor P, Shah N, Pan S, Zero P, Frasier M, Marek K, Kieburtz K, Jennings D, Tanner CM, Simuni T, Singleton A, Toga AW, Chowdhury S, Trojanowski JQ, Shaw LM; Parkinson’s Progression Marker Initiative.

Acta Neuropathol. 2016 Jun;131(6):935-49. doi: 10.1007/s00401-016-1552-2. Epub 2016 Mar 28.

50.

Loss of VPS13C Function in Autosomal-Recessive Parkinsonism Causes Mitochondrial Dysfunction and Increases PINK1/Parkin-Dependent Mitophagy.

Lesage S, Drouet V, Majounie E, Deramecourt V, Jacoupy M, Nicolas A, Cormier-Dequaire F, Hassoun SM, Pujol C, Ciura S, Erpapazoglou Z, Usenko T, Maurage CA, Sahbatou M, Liebau S, Ding J, Bilgic B, Emre M, Erginel-Unaltuna N, Guven G, Tison F, Tranchant C, Vidailhet M, Corvol JC, Krack P, Leutenegger AL, Nalls MA, Hernandez DG, Heutink P, Gibbs JR, Hardy J, Wood NW, Gasser T, Durr A, Deleuze JF, Tazir M, Destée A, Lohmann E, Kabashi E, Singleton A, Corti O, Brice A; French Parkinson's Disease Genetics Study (PDG); International Parkinson's Disease Genomics Consortium (IPDGC).

Am J Hum Genet. 2016 Mar 3;98(3):500-513. doi: 10.1016/j.ajhg.2016.01.014.

Supplemental Content

Loading ...
Support Center